Ser281
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser281  -  NFAT3 (human)

Site Information
SGTPSSAsPALsRRG   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 13419502

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 3 ) , mass spectrometry ( 1 , 2 ) , mass spectrometry (in vitro) ( 3 ) , mutation of modification site ( 3 ) , western blotting ( 3 )
Disease tissue studied:
non-small cell lung cancer ( 1 )
Relevant cell line - cell type - tissue:
Jurkat (T lymphocyte) ( 2 ) , MEF (fibroblast) [RSK2 (human), homozygous knockout] ( 3 ) , NCI-H3122 (pulmonary) ( 1 )

Upstream Regulation
Putative in vivo kinases:
RSK2 (human) ( 3 )
Kinases, in vitro:
RSK2 (human) ( 3 )

Downstream Regulation
Effects of modification on biological processes:
transcription, altered ( 3 )

References 

1

Rikova K (2013) CST Curation Set: 18459; Year: 2013; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST](AGC)
Curated Info

2

Guo A (2012) CST Curation Set: 13981; Year: 2012; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

3

Cho YY, et al. (2007) RSK2 mediates muscle cell differentiation through regulation of NFAT3. J Biol Chem 282, 8380-92
17213202   Curated Info